Literature DB >> 19358784

A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder.

Michael R Liebowitz1, Gregory Asnis, Richard Mangano, Evan Tzanis.   

Abstract

OBJECTIVE: To evaluate the efficacy, safety, and tolerability of venlafaxine extended release (ER) in short-term treatment of panic disorder.
METHOD: In this multicenter, double-blind study, conducted from April 2001 to December 2002, 343 adult outpatients who met criteria for panic disorder (with and without agoraphobia) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were randomly assigned to flexible-dose venlafaxine ER (75-225 mg/d) or placebo for 10 weeks (N = 155 per group, intent-to-treat population). The primary outcome measure was the percentage of panic-free patients as assessed using the Sheehan Panic and Anticipatory Anxiety Scale. Key secondary measures included the Panic Disorder Severity Scale (PDSS) score and Clinical Global Impressions-Improvement (CGI-I) scale response (score = 1 or 2). Last-observation-carried-forward data were analyzed, and statistical significance was set at p <or= .05.
RESULTS: At week 10, the percentage of patients who were free from full-symptom panic attacks was 52% in the venlafaxine ER group and 43% in the placebo group (p = .11). Mean change from baseline in PDSS total score was significantly (p = .006) greater for the venlafaxine ER group (-9.3) than for the placebo group (-7.5), and significantly (p = .03) more venlafaxine ER-treated patients achieved CGI-I response (71%) than did those receiving placebo (59%) at week 10. Treatment with venlafaxine ER was generally safe and well tolerated. Adverse events were the primary or secondary cause for discontinuation for 7 placebo patients (4%) and 12 venlafaxine ER patients (7%).
CONCLUSIONS: Venlafaxine ER appears to be effective, safe, and well tolerated in short-term treatment of panic disorder, although the results fell just short of significance on the primary outcome measure. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00038896. ©Copyright 2009 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358784     DOI: 10.4088/jcp.08m04238

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

1.  Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

Authors:  Michael E Thase; Philip T Ninan; Jeff J Musgnung; Madhukar H Trivedi
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.

Authors:  Domenic A Ciraulo; David H Barlow; Suzy Bird Gulliver; Todd Farchione; Sandra B Morissette; Barbara W Kamholz; Katherine Eisenmenger; Bonnie Brown; Eric Devine; Timothy A Brown; Clifford M Knapp
Journal:  Behav Res Ther       Date:  2013-08-30

Review 3.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 4.  Antidepressants versus placebo for panic disorder in adults.

Authors:  Irene Bighelli; Mariasole Castellazzi; Andrea Cipriani; Francesca Girlanda; Giuseppe Guaiana; Markus Koesters; Giulia Turrini; Toshi A Furukawa; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05

5.  A controlled trial of quetiapine XR coadministration treatment of SSRI-resistant panic disorder.

Authors:  Andrew W Goddard; Waqar Mahmud; Carla Medlock; Yong-Wook Shin; Anantha Shekhar
Journal:  Ann Gen Psychiatry       Date:  2015-09-15       Impact factor: 3.455

Review 6.  Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis.

Authors:  Irene Bighelli; Anna Borghesani; Corrado Barbui
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

7.  Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial.

Authors:  Kwan-Woo Choi; Jong-Min Woo; Youl-Ri Kim; Seung-Hwan Lee; Sang-Yeol Lee; Eui-Jung Kim; Sang-Keun Chung; Eun-Ho Kang; Jae-Hon Lee; Bum-Hee Yu
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-04-30       Impact factor: 2.582

Review 8.  The noradrenergic paradox: implications in the management of depression and anxiety.

Authors:  Alonso Montoya; Robert Bruins; Martin A Katzman; Pierre Blier
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-01       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.